Please login to the form below

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and

Latest news

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Mundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar. ... As per terms of the deal, Mundipharma - a global network of privately owned independent companies - has
MSD launches EU’s first biosimilar Herceptin in UK

Herceptin (trastuzumab) was Roche’s second-biggest product last year, bringing in more than CHF 7bn ($7.4bn), and the onset of biosimilar competition in Europe is expected to start to ... The biggest category of medicines in oncology is monoclonal
Novartis doubles down on biosimilars with Biocon alliance

drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA. ... Biocon meanwhile has launched an insulin glargine biosimilar in Japan to rival Sanofi’s Lantus brand,
Mylan gets first biosimilar Herceptin OK from FDA

The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin
First Herceptin biosimilar cleared in Europe

The South Korea-based joint venture between Samsung and Biogen says the new biosimilar, called Ontruzant, has been approved for the full range of registered indications for Herceptin (trastuzumab), including early ... We hope Ontruzant will play an

More from news
Approximately 15 fully matching, plus 147 partially matching documents found.

Latest Intelligence

2016: The year when deal-makers took stock?

Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).
Deal Watch October 2016

Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
Tough times for pharma in Portugal

In other cases there is a significant decrease in spending on drugs such as Roche's Herceptin (trastuzumab) for breast cancer, which the company explains through price reductions.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

AVEO's financial head joins ImmunoGen

cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer, e-learning/ training, London: Excellent Salary

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Project Manager, Medical Communications, London: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Programme Executive: Salary TBC

Scientific Director: Great salary and bebefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...